Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:DRUG NASDAQ:LXEO NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.05-2.2%$2.43$1.28▼$7.85$335.16M1.161.64 million shs2.94 million shsDRUGBright Minds Biosciences$60.66+5.6%$41.90$0.94▼$79.02$427.29M-6.1455,460 shs66,392 shsLXEOLexeo Therapeutics$6.64-0.3%$4.99$1.45▼$11.72$358.56M1.36646,906 shs314,957 shsPLRXPliant Therapeutics$1.48-0.7%$1.58$1.10▼$16.10$90.86M1.431.56 million shs144,115 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-7.42%+4.70%+51.46%+26.32%-49.19%DRUGBright Minds Biosciences+8.97%+12.40%+47.76%+116.14%+4,609.02%LXEOLexeo Therapeutics-1.62%+25.42%+39.04%+57.82%-26.89%PLRXPliant Therapeutics-1.97%-0.67%-9.15%+27.35%-86.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.05-2.2%$2.43$1.28▼$7.85$335.16M1.161.64 million shs2.94 million shsDRUGBright Minds Biosciences$60.66+5.6%$41.90$0.94▼$79.02$427.29M-6.1455,460 shs66,392 shsLXEOLexeo Therapeutics$6.64-0.3%$4.99$1.45▼$11.72$358.56M1.36646,906 shs314,957 shsPLRXPliant Therapeutics$1.48-0.7%$1.58$1.10▼$16.10$90.86M1.431.56 million shs144,115 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-7.42%+4.70%+51.46%+26.32%-49.19%DRUGBright Minds Biosciences+8.97%+12.40%+47.76%+116.14%+4,609.02%LXEOLexeo Therapeutics-1.62%+25.42%+39.04%+57.82%-26.89%PLRXPliant Therapeutics-1.97%-0.67%-9.15%+27.35%-86.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.75Moderate Buy$12.50309.84% UpsideDRUGBright Minds Biosciences 3.11Buy$81.0033.53% UpsideLXEOLexeo Therapeutics 3.00Buy$15.33130.92% UpsidePLRXPliant Therapeutics 2.08Hold$8.19453.21% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, DRUG, ANNX, and LXEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.009/8/2025DRUGBright Minds BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.008/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.008/18/2025ANNXAnnexonZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/15/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.008/15/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $9.008/10/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral8/8/2025PLRXPliant TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$17.00 ➝ $4.007/31/2025LXEOLexeo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$20.007/2/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 9/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/ALXEOLexeo Therapeutics$650K551.63N/AN/A$3.53 per share1.88PLRXPliant Therapeutics$1.58M57.50N/AN/A$5.00 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%11/13/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/ALXEOLexeo Therapeutics-$98.33M-$3.26N/AN/AN/AN/A-94.65%-73.36%11/12/2025 (Estimated)PLRXPliant Therapeutics-$210.30M-$3.40N/AN/AN/AN/A-73.45%-55.66%11/6/2025 (Estimated)Latest PLRX, DRUG, ANNX, and LXEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ANNXAnnexon-$0.36-$0.34+$0.02-$0.34N/AN/A8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A8/14/2025Q2 2025LXEOLexeo Therapeutics-$0.64-$0.60+$0.04-$0.60N/AN/A8/7/2025Q2 2025PLRXPliant Therapeutics-$0.62-$0.71-$0.09-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.675.67DRUGBright Minds BiosciencesN/A86.6486.64LXEOLexeo TherapeuticsN/A4.434.43PLRXPliant Therapeutics0.1412.9912.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ADRUGBright Minds Biosciences40.52%LXEOLexeo Therapeutics60.67%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%DRUGBright Minds Biosciences42.66%LXEOLexeo Therapeutics5.30%PLRXPliant Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.89 million95.96 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableLXEOLexeo Therapeutics5854.00 million51.14 millionNot OptionablePLRXPliant Therapeutics9061.39 million57.46 millionOptionablePLRX, DRUG, ANNX, and LXEO HeadlinesRecent News About These CompaniesPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 27 at 4:13 AM | marketbeat.comAcadian Asset Management LLC Takes Position in Pliant Therapeutics, Inc. $PLRXSeptember 17, 2025 | marketbeat.comNuveen LLC Makes New Investment in Pliant Therapeutics, Inc. $PLRXSeptember 8, 2025 | marketbeat.comCormorant Asset Management LP Purchases Shares of 3,000,000 Pliant Therapeutics, Inc. $PLRXSeptember 6, 2025 | marketbeat.comAllostery Investments LP Makes New $596,000 Investment in Pliant Therapeutics, Inc. $PLRXSeptember 5, 2025 | marketbeat.comPliant Therapeutics, Inc. $PLRX Shares Sold by Redmile Group LLCSeptember 4, 2025 | marketbeat.comPliant Therapeutics, Inc. $PLRX Stock Holdings Lessened by Deutsche Bank AGSeptember 3, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Recommendation of "Hold" by BrokeragesSeptember 3, 2025 | marketbeat.comNeedham Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comCiti Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comPliant Therapeutics price target raised to $1.70 from $1.50 at CitiAugust 11, 2025 | msn.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)July 24, 2025 | theglobeandmail.comPliant Therapeutics Provides Update on BEACON-IPFJune 27, 2025 | globenewswire.comAlnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 7, 2025 | msn.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025Eli Lilly’s Oral GLP-1 Breakthrough Could Change EverythingBy Chris Markoch | September 18, 2025PLRX, DRUG, ANNX, and LXEO Company DescriptionsAnnexon NASDAQ:ANNX$3.05 -0.07 (-2.24%) Closing price 04:00 PM EasternExtended Trading$3.04 0.00 (-0.16%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Bright Minds Biosciences NASDAQ:DRUG$60.66 +3.21 (+5.59%) Closing price 04:00 PM EasternExtended Trading$59.86 -0.80 (-1.32%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Lexeo Therapeutics NASDAQ:LXEO$6.64 -0.02 (-0.30%) Closing price 04:00 PM EasternExtended Trading$6.67 +0.03 (+0.45%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Pliant Therapeutics NASDAQ:PLRX$1.48 -0.01 (-0.67%) Closing price 04:00 PM EasternExtended Trading$1.46 -0.01 (-1.01%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Draganfly's Army Partnership a Game-Changer for Investors? 154% Jump in Bullish Bets: Is Ford About to Hit the Gas? AppLovin Stock Momentum Builds With $800+ Analyst Price Target Why Vertical Aerospace Could Lead the eVTOL Market by 2028 Apple Stock Positioned for Holiday Gains With iPhone 17 Boost 3 Top-Rated Dividend Growth Stocks to Buy in October Top Insider Buys and Sells From September: Buy, Sell, or Hold? This ETF Weeds Out Small-Cap Underperformers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
